EP0931834A2 — Echinocandin binding domain of 1,3-Beta-glucan synthase
Assigned to Eli Lilly and Co · Expires 1999-07-28 · 27y expired
What this patent protects
The invention relates to a substantially purified ECB binding domain of 1,3-β-glucan synthase, comprising an at least 46 amino acid peptide fragment or fusion protein of glucan synthase that binds echinocandins, useful in a method for identifying new antifungal compounds. Also di…
USPTO Abstract
The invention relates to a substantially purified ECB binding domain of 1,3-β-glucan synthase, comprising an at least 46 amino acid peptide fragment or fusion protein of glucan synthase that binds echinocandins, useful in a method for identifying new antifungal compounds. Also disclosed are nucleic acid molecules that encode said peptide.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.